ActoGeniX, Intrexon deal

Synthetic biology company Intrexon will acquire ActoGeniX for $60 million, comprising $30 million in cash and $30 million in stock. Intrexon will gain ActoGeniX’s TopAct platform, an oral delivery technology based on living, non-pathogenic microorganisms. ActoGeniX’s pipeline includes AG013, an ActoBiotic genetically modified to express and secrete human trefoil factor 3 (TFF3) and AG014 a Lactococcus lactis ActoBiotic genetically modified to express and secrete an anti- tumor necrosis factor (TNF) alpha antibody. ...